We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Single-Cell Analysis Elucidates Mutation Patterns in Myeloid Malignancies

By LabMedica International staff writers
Posted on 01 Dec 2020
Print article
Image: The Tapestri Platform is the first and only single-cell multi-omics platform that is capable of simultaneously providing both genotype and phenotype data from the same cell, across thousands of cells (Photo courtesy of Mission Bio).
Image: The Tapestri Platform is the first and only single-cell multi-omics platform that is capable of simultaneously providing both genotype and phenotype data from the same cell, across thousands of cells (Photo courtesy of Mission Bio).
Myeloid malignancies are clonal diseases of hematopoietic stem or progenitor cells. Myeloid malignancies, including acute myeloid leukemia (AML), arise from the expansion of these hematopoietic stem and progenitor cells that acquire somatic mutations.

Bulk molecular profiling has suggested that mutations are acquired in a stepwise fashion: mutant genes with high variant allele frequencies appear early in leukemogenesis, and mutations with lower variant allele frequencies are thought to be acquired later.

A large team of Hematologist and Oncologists at the Memorial Sloan Kettering Cancer Center (New York, NY, USA) delineated the clonal framework of myeloid malignancies. They performed single-cell mutational profiling on 146 samples from 123 patients, mapping clonal trajectories for each sample and observing mutations that combined to promote clonal expansion and dominance. The investigators also combined protein expression with mutational analysis to map somatic genotype and clonal architecture with immunophenotype. Overall, they said, these findings provided insights into the pathogenesis of myeloid transformation and how clonal complexity evolves with disease progression.

The team used a custom amplicon panel from Mission Bio (South San Francisco, CA, USA) covering 31 frequently mutated genes, to perform single-cell sequencing. They sequenced 740,529 cells from 146 samples from patients at diagnosis and/or relapse. The most common mutations they identified were in DNMT3A, TET2, NPM1, and FLT3. They next investigated disease subtypes, subdividing the cases into samples with epigenetic mutations, samples with signaling mutations, samples without epigenetic mutations, and samples with epigenetic and co-mutated signaling effectors. Of the 80 AML samples with epigenetic mutations, nearly 53% harbored mutations in more than one epigenetic modifier. In nearly all cases, epigenetic regulator mutations were in the same clone, and in 81% of cases the co-occurring mutations were within the dominant clone, suggesting cooperativity between epigenetic mutations.

The number of mutations per sample was significantly higher in AML than in myeloproliferative neoplasms (MPN) and in MPN than in clonal hematopoiesis (CH). The increase in mutations per sample was more pronounced in cases of AML with signaling effector mutations, specifically those in RAS and FLT3. The investigators were then able to identify gene-specific contributions to clonal expansion, finding that IDH2, NPM1, and JAK2 mutations were nearly always present in the dominant clone, whereas FLT3 and RAS mutations were present only in minor subclones in some patients, and in dominant clones in others. In four out of six patients in whom the disease transformed from MPN to AML, they observed a significant alteration in clonal architecture, with emergence of new dominant clones.

The authors concluded that the data suggested that myeloid malignancies manifest as a complex ecosystem of clones that evolves over time, and that scDNA-seq gives a glimpse into this milieu that is not seen with conventional bulk sequencing. Studies of clonal architecture at a single-cell level give us insights into how clonal complexity contributes to the pathogenesis of myeloid transformation. The study was published on October 28, 2020 in the journal Nature.

Related Links:
Memorial Sloan Kettering Cancer Center
Mission Bio


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.